# Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1

> **NCT03306277** · PHASE3 · COMPLETED · sponsor: **Novartis Gene Therapies** · enrollment: 22 (actual)

## Conditions studied

- SMA - Spinal Muscular Atrophy
- Gene Therapy

## Interventions

- **BIOLOGICAL:** Onasemnogene Abeparvovec-xioi

## Key facts

- **NCT ID:** NCT03306277
- **Lead sponsor:** Novartis Gene Therapies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-24
- **Primary completion:** 2019-11-12
- **Final completion:** 2019-11-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03306277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03306277, "Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03306277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*